‘Regentis Biomaterials’ Raises $10M For Tissue Regeneration

Regentis Biomaterials, a privately held company focused on developing proprietary hydrogels for tissue regeneration, announced that it has raised $10 million in its latest round of funding. The funding was raised from new investors Royal DSM through its venturing subsidiary and from Crossroad Fund, as well as from existing investors Medica Venture Partners, SCPVitalife and the Technion Investment Opportunities Fund. The financing will be used to expand the company’s ongoing clinical efforts of GelrinC – a biodegradable implant that allows regeneration of damaged knee joints. Established in 2004, Regentis Biomaterials has offices in Or Akiva, Israel and Princeton, New Jersey.